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Abstract. Background: Dose-dense chemotherapy with
anthracyclines and taxanes has improved either disease free
survival or overall survival in high risk patients with early breast
cancer. Patients and Methods: The activity and safety of a dose-
dense schedule (q14 days) of adriamycin 60 mg/sqm and
cyclophosphamide 600 mg/sqm (AC) x 4 cycles followed by
docetaxel 75 mg/sqm for 4 cycles with hematopoietic support in
patients with stage IIIB breast cancer was explored. Patients
with ER ≥10% tumors received concomitant endocrine therapy
with 3-month triptorelin and letrozole. Results: Fifteen patients
with histologically proven cT4b (three patients) and cT4d
(twelve patients) M0 breast cancer were enrolled. Median age
was 48 years (range 25-66). Eight clinical responses including
one pathological complete remission (pCR), three stable disease
(including minor responses) and four progression of disease,
one during AC and three during taxotere, were observed. Four
patients had grade 3-4 non hematological toxicities and all
except one discontinued treatment. Conclusion: Due to the high
rate of progressive disease, this schedule should not represent a
standard option in cT4 breast cancer. 
Pre-operative treatment is indicated for patients with
locally advanced disease or those needing a reduction of
primary tumor size to undergo conservative breast surgery
(1). The sequential administration of anthracycline-based
regimens and taxanes has allowed higher rates of
pathological complete remissions (pCRs) to be achieved
and one study has suggested an improved overall survival
(OS) for patients with no residual tumor in the surgical
specimen (2-4). 
Chemotherapy schedules with reduced intervals between
successive doses (dose-dense chemotherapy) are
hypothesized to decrease the chance of tumor re-growth
between treatment courses and, therefore, improve
therapeutic results (5). The CALBCG trial 9741 showed an
improved disease free survival (DFS) and OS in high risk
breast cancer women treated with a dose-dense AC→
paclitaxel sequential regimen as adjuvant therapy (6). A
recently published trial of dose-dense vs. standard FEC failed
to show a clear advantage for the accelerated schedule (7).
Dose-dense pre-operative chemotherapy regimens containing
docetaxel following anthracyclines have not been extensively
investigated as primary therapy.
The activity of a dose dense regimen including
anthracyclines and docetaxel in women with T4 breast
cancer, a subpopulation of patients which, due to the poor
prognosis, deserves a more aggressive approach was
investigated in this study.
Patients and Methods
Patients with stage IIIB breast cancer (cT4 a-d, N0-2, M0),
consecutively admitted at the Department of Medicine of the
European Institute of Oncology from October 2004 to September
2005 were enrolled in this study. A punch biopsy or a trucut was
performed for diagnosis and for assessment of biological
characteristics of the tumor and an instrumental work up was
performed to exclude the presence of distant metastases.
All patients received standard AC (doxorubicin at a dose of 
60 mg/sqm plus cyclophosphamide at a dose of 600 mg/sqm through
intravenous (i.v.) infusion every two weeks for four courses followed
by four courses of docetaxel at a dose of 75 mg/sqm i.v. over 1 h
every two weeks. Filgrastim at a dose of 5 Ìg/kg was given by
subcutaneous injection on days 4-10 of each 14-day course. Patients
with ER and/or PgR ≥10% (HR+ve) tumors received concomitant
endocrine therapy with 3-month triptorelin and letrozole 2.5 mg/day
at achievement of post-menopausal estradiol levels.
Definitive surgery, (radical modified mastectomy with complete
axillary lymph node dissection) was performed approximately four
weeks after the fourth course of docetaxel. Locoregional
radiotherapy was prescribed to complete local treatment.
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At baseline, at the end of the four cycles with AC and at the end
of the four cycles of taxotere patients were submitted to instrumental
evaluation with breast ultrasound and to mammography, when
feasible. Clinical response was defined according to WHO criteria ,
as ≥50% reduction of the product of the two largest diameters of
the tumor, when measurable, at physical and instrumental evaluation
and the disappearance of erythema, edema and decreased swelling
of the breast in cancers without measurable nodules. pCR was
defined as absence of invasive tumor in the surgical specimen,
according to Sataloff et al. (8).
This is a two stage phase II clinical trial, taking into account
both toxicity and treatment response, according to the
methodology described by Bryant and Day (9). A pCR rate of 0.1
was considered as unacceptable activity, and a pCR rate of 0.3 as
acceptable; 40% of patients with grade 3-4 toxicity as unacceptable
toxicity, and 20% of patients with grade 3-4 side effects as
acceptable. Significance levels of 10% for treatment and 15% for
toxic effects and a 90% power were adopted. 
After testing the regimen on 15 patients in the first stage, the
trial would be terminated for poor activity if none or only one
achieved pCR, and would be terminated for toxicity if nine or
fewer patients were spared grade 3-4 toxic effects. If the trial
proceeds to the second stage, a total of 33 patients should be
studied. If the total number responding is less than or equal to 5, or
if the total number without grade 3-4 toxicity is less than or equal
to 22, the regimen should be rejected.
Results
Fifteen patients were enrolled in this study. Major patient
characteristics are shown in Table I. Median age was 48
years (range 25-66 years). Eight patients were pre-
menopausal and 7 were post-menopausal. Among the pre-
menopausal patients six out of eight had HR+ve tumors (3
T4b and 3 T4d) and received endocrine therapy, while six
out of seven of the post-menopausal patients had ER and
PgR <10% (HR-ve) tumors. Only four patients had her-
2/neu 3+ tumors.
Tumor characteristics at surgery are reported in Table I.
Four out of 15 patients were not submitted to surgery at the
end of the study treatment, three because of progressive
disease, while one patient stopped treatment because of
grade 3 cutaneous toxicity. All these patients were treated
with different chemotherapeutic regimens: one patient with
her-2/neu overexpressing breast cancer received weekly
trastuzumab + paclitaxel attained stable disease and was
submitted to surgery, and the remaining three received
continuous 5-fluorouracil (5-FU) infusion containing
regimens (ViFuP or ECF), with one positive response
followed by surgery, while the other two patients have not
been submitted to surgery yet. 
Clinical and pathological responses are summarized in
Table II. Among responding patients 50% obtained or
improved the response with taxotere, while the remaining
four patients showed the best response after AC. One
patient progressed at the end of AC and received taxotere
with minor response, while 3 patients progressed during or
at the end of taxotere administration and received
trastuzumab + paclitaxel (1) and continuous 5-FU infusion
containing regimens (2) (see above). One patient was
withdrawn after AC because of occurrence of two episodes
of grade 3 sopraventricular parossistic arythmia. Two
patients were withdrawn because of grade 3 and 4 cutaneous
toxicity after the first cycle of taxotere, while two patients
with grade 2 unresolved toxicity required a dose reduction
of up to 50% to complete treatment. One patient had grade
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Table I. Patient characteristics at baseline and at surgery.
Baseline Surgery
No. of patients 15 11
Evaluable for response/toxicity 15/15
Median age (range) 48 years (25-66)
Clinical stage 








3+/ absent- 2+* 4/11 5/5
HR+ve ER ≥10% of the cells; H-ve ER <10% of the cells.
IHC Her-2/neu 2+ was further tested as FISH negative











CR=complete response; PR=partial response;
SD=stable disease; PD=progressive disease;
pCR=pathological complete remission.
*The patient achieving pCR obtained also a complete clinical response.
3 biochemical toxicity and required dose reduction for
subsequent courses. According to the two-stage design (9),
patient recruitment was discontinued after the first stage,
based on the rate of progressive disease and grade 3-4
toxicity. 
Discussion
Inoperable stage IIIB breast cancer, and particularly
inflammatory breast cancer, represents a subset of tumors
with poor long term prognosis (10). No standard treatment
is established although anthracycline based chemotherapy
followed by surgery and radiotherapy are recommended
(11). Since dose-dense chemotherapy has been shown to be
beneficial in high-risk patients (6), the activity of the
accelerated administration of a regimen which had been
shown very active in pre-operative therapy was investigated
in patients with T4 tumors (2). Our results do not support
an advantage for this accelerated regimen due to the
unexpected high rate of progressions and grade 3-4
toxicities. The results achieved compared unfavorably with
results we previously obtained in patients with locally
advanced disease (T4) treated with a regimen containing
vinorelbine, cisplatin and 5-FU as continuous infusion
(ViFuP regimen) (12). In the previous study eleven patients
(43%) had inflammatory breast cancer. Objective response
was observed in 19 out of the 26 evaluable patients (73%;
95% CI: 52-88%), five had complete pathological response
(20%; 95% CI: 7-41%), while no disease progression under
treatment occurred and side effects were mild. We have
also shown, in a large series of 399 patients with T2-T4
breast cancer treated pre-operatively with various regimens,
that infusional 5-FU containing regimens significantly
correlated with a greater rate of pCR and of nodal negative
status at surgery (13). Moreover, in this series the rate of
progressive disease was only 1.5%. The high percentage of
progressive disease observed in the present study cannot be
explained simply by the selection of high risk patients (12
out of 15 patients had T4d disease). In fact, in a recent
review the rate of progressive disease during induction
chemotherapy for inflammatory breast cancer was reported
to be up to 6% (10). 
A phase II study evaluating the role of dose-dense
sequential doxorubicin and docetaxel for patients with
advanced operable and inoperable breast cancer was
recently reported (14). An overall response rate of 92% was
reported including 13 (33%) complete responses, 23 (59%)
partial responses and 4 (10%) pCR. However, two out of
the nine patients with inflammatory breast cancer
progressed during docetaxel (27%), a figure which is
comparable with our series. The regimen was defined as
well tolerated, but despite a protocol change requiring 3
weeks between doxorubicin and docetaxel, overall 5 out of
39 patients were unable to complete all cycles of docetaxel
and eight patients required dose reduction of docetaxel (due
to development of grade 3-4 mucositis and hand-foot
syndrome). 
Other studies have shown that the dose-dense
administration of taxotere might be associated with a high
incidence of grade 3-4 cutaneous toxicity (42%), although
in this study an increased rate of both clinical and pCR was
observed (15). Conversely, an improvement in pCR rate
from prolonging duration of treatment rather than
shortening treatment intervals was shown in the
GEPARDUO trial (16) and no advantage in the response
rate was reported in two recent trials with the use of dose-
dense anthracyclines (9).
In conclusion, in our experience dose-dense docetaxel
chemotherapy correlates with significant toxicity, in
particular and with a high rate of disease progression (20%)
in locally advanced disease. However, these data together
with other published evidence, indicate that further studies
on locally advanced disease are needed in order to optimize
dose and schedule of pre-operative dose-dense docetaxel-
containing chemotherapy before widespread introduction in
current clinical routine. Other treatment options , including
regimens containing infusional 5-FU, should be evaluated.
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